<div class="rprt_all"><div class="rprt abstract"><div class="cit"><a href="#" title="The American journal of cardiology." abstractLink="yes" alsec="jour" alterm="Am J Cardiol.">Am J Cardiol.</a> 1999 Sep 2;84(5A):2M-6M.</div><h1>Anticoagulants in acute coronary syndromes.</h1><div class="auths"><a href="/pubmed/?term=Turpie%20AG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=10505536">Turpie AG</a><sup>1</sup>.</div><div class="afflist"><h3><a title="Open/close author information list" class="jig-ncbitoggler" href="#">Author information</a></h3><dl class="ui-ncbi-toggler-slave"><dt>1</dt><dd>McMaster University, Hamilton, Ontario, Canada.</dd></dl></div><div class="abstr"><h3>Abstract</h3><div class=""><p>Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI). Early studies demonstrated that aspirin reduces the risk of mortality or nonfatal MI by 50-70% in patients presenting with unstable angina or non-Q-wave MI. Added to aspirin, heparin regimens further diminish the incidence of these myocardial ischemic events in the acute setting. Three major clinical studies demonstrated that such enhanced risk reductions can be achieved without significant increases in bleeding complications. The low-molecular-weight (LMW) heparin, dalteparin, proved superior to placebo but not unfractionated heparin in diminishing the incidence of (1) death or MI; (2) death, MI, or recurrence of angina; or (3) frequency of revascularization procedures. On the other hand, another LMW heparin, enoxaparin, did reduce these events at 14 and 30 days, as well as 1 year after treatment. The principal biophysical limitation of heparins, however, is that they cannot inactivate clot-bound thrombin, which probably contributes to morbidity and mortality in acute coronary syndromes. The natural leech-derived polypeptide hirudin and its derivatives (e.g., lepirudin) inactivate both fibrin-bound and free thrombin. Lepirudin has been approved in certain countries for the treatment of heparin-induced thrombocytopenia and is now being evaluated in the clinical management of acute myocardial ischemic syndromes. The well-documented pathophysiologic foundation for acute coronary syndromes is partial or intermittent thrombotic occlusion of a coronary artery as the result of atherosclerosis. Although a stable atherosclerotic plaque may not be clinically problematic, plaque rupture, which occurs under a variety of stimuli, touches off a cascade of enzymatic and cellular responses that frequently culminate in thrombotic occlusion. In the coronary circulation, such an occlusion may cause transmural MI, unstable angina, or non-Q-wave MI. Because the pathogenetic mechanisms of atherosclerosis with thrombotic complications have been elucidated, this knowledge can be translated into a rational clinical approach using antithrombotic therapies.</p></div></div><div class="aux"><div class="resc"><dl class="rprtid"><dt>PMID:</dt> <dd>10505536</dd>  <dt>DOI:</dt> <dd><a href="//doi.org/10.1016/s0002-9149(99)00490-7" ref="aid_type=doi" target="_blank">10.1016/s0002-9149(99)00490-7</a></dd> </dl></div><div class="resc status"><dl class="rprtid"><dd> [Indexed for MEDLINE] </dd></dl></div><div class="links"></div><div id="ncbi_share_pm"><a href="#" class="ncbi_share" style="visibility:hidden" data-ncbi_share_config="popup:false,shorten:true" ref="id=10505536&amp;db=pubmed">Share</a></div></div><div class="other_content"><div class="morecit"><h3><a title="Supplemental information" class="jig-ncbitoggler ui-ncbitoggler" href="#"><span class="ui-ncbitoggler-master-text">Publication type, MeSH terms, Substances</span><span class="ui-icon ui-icon-triangle-1-e"></span></a></h3><div class="ui-ncbi-toggler-slave"><h4>Publication type</h4><ul><li><a href="#" abstractLink="yes" alsec="ptyp" alterm="Review">Review</a></li></ul><h4>MeSH terms</h4><ul><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Acute Disease">Acute Disease</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Angina, Unstable/drug therapy">Angina, Unstable/drug therapy</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Anticoagulants/therapeutic use*">Anticoagulants/therapeutic use*</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Aspirin/therapeutic use*">Aspirin/therapeutic use*</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Clinical Trials as Topic">Clinical Trials as Topic</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Coronary Disease/drug therapy*">Coronary Disease/drug therapy*</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Dalteparin/therapeutic use">Dalteparin/therapeutic use</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Enoxaparin/therapeutic use">Enoxaparin/therapeutic use</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Fibrinolytic Agents/therapeutic use">Fibrinolytic Agents/therapeutic use</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Heparin, Low-Molecular-Weight/therapeutic use*">Heparin, Low-Molecular-Weight/therapeutic use*</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Hirudin Therapy*">Hirudin Therapy*</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Hirudins/analogs &amp; derivatives">Hirudins/analogs &amp; derivatives</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Humans">Humans</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Myocardial Infarction/drug therapy">Myocardial Infarction/drug therapy</a></li><li><a href="#" abstractLink="yes" alsec="mesh" alterm="Recombinant Proteins/therapeutic use">Recombinant Proteins/therapeutic use</a></li></ul><h4>Substances</h4><ul><li><a href="#" abstractLink="yes" alsec="subs" alterm="Anticoagulants">Anticoagulants</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Enoxaparin">Enoxaparin</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Fibrinolytic Agents">Fibrinolytic Agents</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Heparin, Low-Molecular-Weight">Heparin, Low-Molecular-Weight</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Hirudins">Hirudins</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Recombinant Proteins">Recombinant Proteins</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Aspirin">Aspirin</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="Dalteparin">Dalteparin</a></li><li><a href="#" abstractLink="yes" alsec="subs" alterm="lepirudin">lepirudin</a></li></ul></div></div><div class="morecit"><h3><a title="Links to resources such as full text articles and biological data" class="jig-ncbitoggler ui-ncbitoggler" href="#"><span class="ui-ncbitoggler-master-text">LinkOut - more resources</span><span class="ui-icon ui-icon-triangle-1-e"></span></a></h3><div class="ui-ncbi-toggler-slave"><div class="linkoutlist"><h4>Full Text Sources</h4><ul><li><a title="Full text at publisher's site" href="https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(99)00490-7" ref="itool=Abstract&amp;PrId=3048&amp;uid=10505536&amp;db=pubmed&amp;log$=linkoutlink&amp;nlmid=0207277" target="_blank">Elsevier Science</a></li></ul><h4>Medical</h4><ul><li><a title="Free resource" href="https://medlineplus.gov/bloodthinners.html" ref="itool=Abstract&amp;PrId=3162&amp;uid=10505536&amp;db=pubmed&amp;log$=linkoutlink&amp;nlmid=0207277" target="_blank">Blood Thinners - MedlinePlus Health Information</a></li></ul><h4>Miscellaneous</h4><ul><li><a title="Free resource" href="https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+50-78-2" ref="itool=Abstract&amp;PrId=4419&amp;uid=10505536&amp;db=pubmed&amp;log$=linkoutlink&amp;nlmid=0207277" target="_blank">ACETYLSALICYLIC ACID - Hazardous Substances Data Bank</a></li></ul></div></div></div></div><input id="absid" type="hidden" value="10505536" /><input id="absdate" type="hidden" value="1999/10/3" /><ul class="print-log"><li></li></ul></div></div>